The Filings Report

Bio-Rad Laboratories, Inc.Class A

BIONYSECIK 12208Healthcare / Diagnostics & Researchfiscal year ends December70 quarters since 2009

Revenue, Q3 FY2026
$656M
+0.5% on Q3 FY2025
Net income
$459M
+234.1% on Q3 FY2025
Free cash flow
$65M
−26.9% on Q3 FY2025
Diluted EPS
$17.02
+234.0% on Q3 FY2025
Revenue, TTM
$2.6B
trailing four quarters
Net margin, TTM
39.5%
net income $1.0B
Free cash flow, TTM
$329M
$468M less $139M capex
Cash and equivalents
$465M
long-term debt $803M, Sep 30, 2026
Shares, 12-month change
+0.1%
27M diluted weighted shares (no single count on the cover), Sep 30, 2026
Buybacks, TTM
$79M
0.8% of market value
Dividends, TTM
—
no yield
Market value
$10.3B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Bio-Rad Laboratories, Inc.Class A reported revenue of $656M, +0.5% on Q3 FY2025, and net income of $459M (+234.1%). Operating margin was −7.6%. Free cash flow, operating cash flow less capital expenditures, was $65M ($96M less $31M). Diluted earnings per share were $17.02.

Share price

Daily candlesticks from November 11, 2024 to November 9, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

BIO daily priceSplit-adjusted, US dollars; an earnings release
Nov 9, 2026O $385.38 · H $394.73 · L $381.59 · C $388.31 · +1.77% on the dayOver the range: +27.08%, Nov 10, 2025 to Nov 9, 2026
$227$272$316$361$406Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 4, 2026.

Revenue and net incomeRevenueNet income
−$3B−$2B−$1B$0$1BQ4'22, Revenue: $730MQ4'22, Net income: $828MQ4'22Q1'23, Revenue: $677MQ1'23, Net income: $69MQ1'23Q2'23, Revenue: $681MQ2'23, Net income: −$1.2BQ2'23Q3'23, Revenue: $632MQ3'23, Net income: $106MQ3'23Q4'23, Revenue: $681MQ4'23, Net income: $350MQ4'23Q1'24, Revenue: $611MQ1'24, Net income: $384MQ1'24Q2'24, Revenue: $639MQ2'24, Net income: −$2.2BQ2'24Q3'24, Revenue: $650MQ3'24, Net income: $653MQ3'24Q4'24, Revenue: $668MQ4'24, Net income: −$716MQ4'24Q1'25, Revenue: $585MQ1'25, Net income: $64MQ1'25Q2'25, Revenue: $652MQ2'25, Net income: $318MQ2'25Q3'25, Revenue: $653MQ3'25, Net income: −$342MQ3'25Q4'25, Revenue: $693MQ4'25, Net income: $720MQ4'25Q1'26, Revenue: $592MQ1'26, Net income: −$527MQ1'26Q2'26, Revenue: $651MQ2'26, Net income: $371MQ2'26Q3'26, Revenue: $656MQ3'26, Net income: $459MQ3'26−$3B−$2B−$1B$0$1BQ4'22, Revenue: $730MQ4'22, Net income: $828MQ4'22Q1'23, Revenue: $677MQ1'23, Net income: $69MQ1'23Q2'23, Revenue: $681MQ2'23, Net income: −$1.2BQ2'23Q3'23, Revenue: $632MQ3'23, Net income: $106MQ3'23Q4'23, Revenue: $681MQ4'23, Net income: $350MQ4'23Q1'24, Revenue: $611MQ1'24, Net income: $384MQ1'24Q2'24, Revenue: $639MQ2'24, Net income: −$2.2BQ2'24Q3'24, Revenue: $650MQ3'24, Net income: $653MQ3'24Q4'24, Revenue: $668MQ4'24, Net income: −$716MQ4'24Q1'25, Revenue: $585MQ1'25, Net income: $64MQ1'25Q2'25, Revenue: $652MQ2'25, Net income: $318MQ2'25Q3'25, Revenue: $653MQ3'25, Net income: −$342MQ3'25Q4'25, Revenue: $693MQ4'25, Net income: $720MQ4'25Q1'26, Revenue: $592MQ1'26, Net income: −$527MQ1'26Q2'26, Revenue: $651MQ2'26, Net income: $371MQ2'26Q3'26, Revenue: $656MQ3'26, Net income: $459MQ3'26−$3B−$2B−$1B$0$1BQ4'22, Revenue: $730MQ4'22, Net income: $828MQ1'23, Revenue: $677MQ1'23, Net income: $69MQ1'23Q2'23, Revenue: $681MQ2'23, Net income: −$1.2BQ3'23, Revenue: $632MQ3'23, Net income: $106MQ3'23Q4'23, Revenue: $681MQ4'23, Net income: $350MQ1'24, Revenue: $611MQ1'24, Net income: $384MQ1'24Q2'24, Revenue: $639MQ2'24, Net income: −$2.2BQ3'24, Revenue: $650MQ3'24, Net income: $653MQ3'24Q4'24, Revenue: $668MQ4'24, Net income: −$716MQ1'25, Revenue: $585MQ1'25, Net income: $64MQ1'25Q2'25, Revenue: $652MQ2'25, Net income: $318MQ3'25, Revenue: $653MQ3'25, Net income: −$342MQ3'25Q4'25, Revenue: $693MQ4'25, Net income: $720MQ1'26, Revenue: $592MQ1'26, Net income: −$527MQ1'26Q2'26, Revenue: $651MQ2'26, Net income: $371MQ3'26, Revenue: $656MQ3'26, Net income: $459MQ3'26

Net income losses drawn in red.

Free cash flow
$0$50M$100M$150MQ4'22, Free cash flow: $45MQ4'22Q1'23, Free cash flow: $62MQ1'23Q2'23, Free cash flow: $63MQ2'23Q3'23, Free cash flow: $54MQ3'23Q4'23, Free cash flow: $39MQ4'23Q1'24, Free cash flow: $30MQ1'24Q2'24, Free cash flow: $55MQ2'24Q3'24, Free cash flow: $123MQ3'24Q4'24, Free cash flow: $81MQ4'24Q1'25, Free cash flow: $96MQ1'25Q2'25, Free cash flow: $71MQ2'25Q3'25, Free cash flow: $89MQ3'25Q4'25, Free cash flow: $119MQ4'25Q1'26, Free cash flow: $78MQ1'26Q2'26, Free cash flow: $67MQ2'26Q3'26, Free cash flow: $65MQ3'26$0$50M$100M$150MQ4'22, Free cash flow: $45MQ4'22Q1'23, Free cash flow: $62MQ1'23Q2'23, Free cash flow: $63MQ2'23Q3'23, Free cash flow: $54MQ3'23Q4'23, Free cash flow: $39MQ4'23Q1'24, Free cash flow: $30MQ1'24Q2'24, Free cash flow: $55MQ2'24Q3'24, Free cash flow: $123MQ3'24Q4'24, Free cash flow: $81MQ4'24Q1'25, Free cash flow: $96MQ1'25Q2'25, Free cash flow: $71MQ2'25Q3'25, Free cash flow: $89MQ3'25Q4'25, Free cash flow: $119MQ4'25Q1'26, Free cash flow: $78MQ1'26Q2'26, Free cash flow: $67MQ2'26Q3'26, Free cash flow: $65MQ3'26$0$50M$100M$150MQ4'22, Free cash flow: $45MQ1'23, Free cash flow: $62MQ1'23Q2'23, Free cash flow: $63MQ3'23, Free cash flow: $54MQ3'23Q4'23, Free cash flow: $39MQ1'24, Free cash flow: $30MQ1'24Q2'24, Free cash flow: $55MQ3'24, Free cash flow: $123MQ3'24Q4'24, Free cash flow: $81MQ1'25, Free cash flow: $96MQ1'25Q2'25, Free cash flow: $71MQ3'25, Free cash flow: $89MQ3'25Q4'25, Free cash flow: $119MQ1'26, Free cash flow: $78MQ1'26Q2'26, Free cash flow: $67MQ3'26, Free cash flow: $65MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5BQ4'22, Cash and equivalents: $434MQ4'22, Long-term debt: $1.2BQ4'22Q1'23, Cash and equivalents: $464MQ1'23, Long-term debt: $1.2BQ1'23Q2'23, Cash and equivalents: $390MQ2'23, Long-term debt: $1.2BQ2'23Q3'23, Cash and equivalents: $458MQ3'23, Long-term debt: $1.2BQ3'23Q4'23, Cash and equivalents: $404MQ4'23, Long-term debt: $1.2BQ4'23Q1'24, Cash and equivalents: $433MQ1'24, Long-term debt: $1.2BQ1'24Q2'24, Cash and equivalents: $407MQ2'24, Long-term debt: $1.2BQ2'24Q3'24, Cash and equivalents: $410MQ3'24, Long-term debt: $1.2BQ3'24Q4'24, Cash and equivalents: $488MQ4'24, Long-term debt: $1.2BQ4'24Q1'25, Cash and equivalents: $521MQ1'25, Long-term debt: $1.2BQ1'25Q2'25, Cash and equivalents: $369MQ2'25, Long-term debt: $1.2BQ2'25Q3'25, Cash and equivalents: $396MQ3'25, Long-term debt: $1.2BQ3'25Q4'25, Cash and equivalents: $530MQ4'25, Long-term debt: $1.2BQ4'25Q1'26, Cash and equivalents: $507MQ1'26, Long-term debt: $803MQ1'26Q2'26, Cash and equivalents: $517MQ2'26, Long-term debt: $803MQ2'26Q3'26, Cash and equivalents: $465MQ3'26, Long-term debt: $803MQ3'26$0$500M$1.0B$1.5BQ4'22, Cash and equivalents: $434MQ4'22, Long-term debt: $1.2BQ4'22Q1'23, Cash and equivalents: $464MQ1'23, Long-term debt: $1.2BQ1'23Q2'23, Cash and equivalents: $390MQ2'23, Long-term debt: $1.2BQ2'23Q3'23, Cash and equivalents: $458MQ3'23, Long-term debt: $1.2BQ3'23Q4'23, Cash and equivalents: $404MQ4'23, Long-term debt: $1.2BQ4'23Q1'24, Cash and equivalents: $433MQ1'24, Long-term debt: $1.2BQ1'24Q2'24, Cash and equivalents: $407MQ2'24, Long-term debt: $1.2BQ2'24Q3'24, Cash and equivalents: $410MQ3'24, Long-term debt: $1.2BQ3'24Q4'24, Cash and equivalents: $488MQ4'24, Long-term debt: $1.2BQ4'24Q1'25, Cash and equivalents: $521MQ1'25, Long-term debt: $1.2BQ1'25Q2'25, Cash and equivalents: $369MQ2'25, Long-term debt: $1.2BQ2'25Q3'25, Cash and equivalents: $396MQ3'25, Long-term debt: $1.2BQ3'25Q4'25, Cash and equivalents: $530MQ4'25, Long-term debt: $1.2BQ4'25Q1'26, Cash and equivalents: $507MQ1'26, Long-term debt: $803MQ1'26Q2'26, Cash and equivalents: $517MQ2'26, Long-term debt: $803MQ2'26Q3'26, Cash and equivalents: $465MQ3'26, Long-term debt: $803MQ3'26$0$500M$1.0B$1.5BQ4'22, Cash and equivalents: $434MQ4'22, Long-term debt: $1.2BQ1'23, Cash and equivalents: $464MQ1'23, Long-term debt: $1.2BQ1'23Q2'23, Cash and equivalents: $390MQ2'23, Long-term debt: $1.2BQ3'23, Cash and equivalents: $458MQ3'23, Long-term debt: $1.2BQ3'23Q4'23, Cash and equivalents: $404MQ4'23, Long-term debt: $1.2BQ1'24, Cash and equivalents: $433MQ1'24, Long-term debt: $1.2BQ1'24Q2'24, Cash and equivalents: $407MQ2'24, Long-term debt: $1.2BQ3'24, Cash and equivalents: $410MQ3'24, Long-term debt: $1.2BQ3'24Q4'24, Cash and equivalents: $488MQ4'24, Long-term debt: $1.2BQ1'25, Cash and equivalents: $521MQ1'25, Long-term debt: $1.2BQ1'25Q2'25, Cash and equivalents: $369MQ2'25, Long-term debt: $1.2BQ3'25, Cash and equivalents: $396MQ3'25, Long-term debt: $1.2BQ3'25Q4'25, Cash and equivalents: $530MQ4'25, Long-term debt: $1.2BQ1'26, Cash and equivalents: $507MQ1'26, Long-term debt: $803MQ1'26Q2'26, Cash and equivalents: $517MQ2'26, Long-term debt: $803MQ3'26, Cash and equivalents: $465MQ3'26, Long-term debt: $803MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Bio-Rad Laboratories, Inc.Class A income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue656651592693653652585668+0.5%
Cost of revenue328305283348310306279326+5.9%
Gross profit329346309345343345306342−4.3%
Research and development7161637071617480+0.1%
Selling, general and administrative257212212221207208209204+24.3%
Operating income(50)7334(119)65772458−176.1%
Other income (expense)102324298163720+25.3%
Pretax income539542(690)929(431)41483(909)+225.0%
Income tax80171(163)209(89)9619(193)+189.8%
Net income459371(527)720(342)31864(716)+234.1%
Diluted EPS ($)17.0213.85(19.55)—(12.70)11.672.29(25.57)+234.0%
Diluted shares (millions)272727—272728——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Bio-Rad Laboratories, Inc.Class A balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents465517507530396369521488+17.6%
Short-term investments1,1991,1021,0581,0111,0231,0051,1391,176+17.2%
Total current assets3,0793,0212,9422,9062,8422,8113,0373,030+8.3%
Total assets10,78310,2529,79010,5779,69610,2149,5279,364+11.2%
Total current liabilities969961917517522549507468+85.5%
Long-term debt8038038031,2021,2011,2011,2011,200−33.2%
Total liabilities3,1803,0782,9393,1232,9603,0852,8482,795+7.5%
Stockholders’ equity7,6037,1746,8517,4546,7377,1296,6796,569+12.9%
Shares outstanding (millions)—————————

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 4, 2026.

Bio-Rad Laboratories, Inc.Class A cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 4, 2026Q2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 14, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow9699108165121117130124−20.3%
Capital expenditures3132304632463443−1.6%
Free cash flow (CFO − capex)65677811989719681−26.9%
Depreciation and amortization—————————
Share repurchases032480531401020−100.0%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 13, 2026.

Income statement

Bio-Rad Laboratories, Inc.Class A income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Apr 1, 2019FY2017ended Dec 31, 2017filed Apr 16, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Mar 18, 2014FY2012ended Dec 31, 2012filed Mar 18, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 6, 2010FY2008ended Dec 31, 2008filed Aug 6, 2010
Revenue2,5832,5672,6712,8022,9232,5462,3122,2892,1602,0682,0192,1752,1332,0692,0741,9271,7841,764
Cost of revenue1,2431,1881,2441,2351,2841,1081,0551,066972930————————
Gross profit1,3401,3791,4271,5671,6381,4381,2571,2231,1881,1381,1221,1791,1781,1551,1791,0911,000963
Research and development276296247257261218203199250206193220211209178172164160
Selling, general and administrative844814842828877799825835807815762808798682696635601591
Operating income47269338483500421230(103)11956167150169264305284231183
Other income (expense)90901074527242637111411013228470
Pretax income996(2,342)(850)(4,704)5,4494,9182,2615139842146132112230246220186143
Income tax236(498)(213)(1,077)1,1951,104502147(24)163743356467333745
Net income760(1,844)(637)(3,627)4,2543,8141,75936612226109897816517918514590
Diluted EPS ($)27.85(65.36)(21.82)(121.79)140.83126.4758.2712.104.070.883.713.052.695.786.296.595.203.24
Diluted shares (millions)272829303030303030302929292928282828

Balance sheet

Bio-Rad Laboratories, Inc.Class A balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Apr 1, 2019FY2017ended Dec 31, 2017filed Apr 16, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Mar 18, 2014FY2012ended Dec 31, 2012filed Mar 18, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 6, 2010FY2008ended Dec 31, 2008filed Aug 6, 2010
Cash and equivalents530488404434471662661432384456458413332463574907650205
Short-term investments1,0111,1761,2031,35639932945441337138332928427745823911995—
Total current assets2,9063,0303,0483,1581,9902,1402,1802,0231,9771,8451,7781,7161,7571,9371,7981,9751,563—
Total assets10,5779,36412,29913,50217,79912,9738,0095,6114,2733,8513,7103,3413,3893,4443,0973,0632,536—
Total current liabilities517468523569681632905451503471441447487472459667420—
Long-term debt1,2021,2001,1991,198111214439————436732732731738—
Total liabilities3,1232,7953,5583,8864,1143,0932,2541,5911,3431,2711,2191,1561,2021,4281,3521,5221,257—
Stockholders’ equity7,4546,5698,7419,61513,6859,8905,7574,0202,9302,5792,4852,1842,1872,0151,7441,5371,260—
Shares outstanding (millions)——————————————————

Cash flow statement

Bio-Rad Laboratories, Inc.Class A cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 14, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Dec 31, 2022filed Feb 17, 2023FY2021ended Dec 31, 2021filed Feb 11, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Apr 1, 2019FY2017ended Dec 31, 2017filed Apr 16, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Mar 18, 2014FY2012ended Dec 31, 2012filed Mar 18, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 6, 2010FY2008ended Dec 31, 2008filed Aug 6, 2010
Operating cash flow532455375194669585458285104216186273169266263226325191
Capital expenditures158166157113134109991301111411121211071431038868(85)
Free cash flow (CFO − capex)37529021882536476359156(7)757415262124160137257276
Depreciation and amortization165152146137138139134138149143132150147130121109102—
Share repurchases29620442921650100284930000000——
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$136K
1 sales by 1 insider; officers and directors $136K

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 24, 2026DiVincenzo Jonathan P.President & COOoption exercise1,869$0.00—3,832Oct 27, 2026
Oct 24, 2026DiVincenzo Jonathan P.President & COOtax withholding951$369.95$352K2,881Oct 27, 2026
Oct 20, 2026Evran SedatEVP, Global Supply Chainoption exercise1,044$0.00—4,647Oct 22, 2026
Oct 20, 2026Evran SedatEVP, Global Supply Chaintax withholding487$354.50$173K4,160Oct 22, 2026
Sep 6, 2026Allison SchwartzDirectoroption exercise92$0.00—1,768Sep 9, 2026
Sep 6, 2026Allison SchwartzDirectortax withholding34$386.11$13K1,734Sep 9, 2026
Sep 6, 2026Barry JamesEVP, President, LSGoption exercise1,056$0.00—2,495Sep 9, 2026
Sep 6, 2026Barry JamesEVP, President, LSGtax withholding470$386.11$181K2,025Sep 9, 2026
Sep 6, 2026Evran SedatEVP, Global Supply Chainoption exercise864$0.00—3,880Sep 9, 2026
Sep 6, 2026Evran SedatEVP, Global Supply Chaintax withholding277$386.11$107K3,603Sep 9, 2026
Sep 6, 2026Engelhardt Eva AnetteEVP, President, CDGoption exercise1,152$0.00—2,313Sep 9, 2026
Sep 6, 2026Engelhardt Eva AnetteEVP, President, CDGtax withholding485$386.11$187K1,828Sep 9, 2026
Sep 6, 2026Enloe Courtney CEVP, General Counsel & Secoption exercise768$0.00—1,957Sep 9, 2026
Sep 6, 2026Enloe Courtney CEVP, General Counsel & Sectax withholding305$386.11$118K1,652Sep 9, 2026
Sep 6, 2026Lakkaraju Roop KalyanEVP, Chief Financial Officeroption exercise1,536$0.00—4,933Sep 9, 2026
Sep 6, 2026Lakkaraju Roop KalyanEVP, Chief Financial Officertax withholding782$386.11$302K4,151Sep 9, 2026
Sep 6, 2026Schwartz Norman DChairman & CEO, Director, 10% owneroption exercise3,455$0.00—450,873Sep 9, 2026
Sep 6, 2026Schwartz Norman DChairman & CEO, Director, 10% ownertax withholding1,854$386.11$716K449,019Sep 9, 2026
Sep 5, 2026Allison SchwartzDirectoroption exercise228$0.00—1,758Sep 9, 2026
Sep 5, 2026Allison SchwartzDirectortax withholding82$386.11$32K1,676Sep 9, 2026
Sep 5, 2026Barry JamesEVP, President, LSGoption exercise1,027$0.00—1,808Sep 9, 2026
Sep 5, 2026Barry JamesEVP, President, LSGtax withholding369$386.11$142K1,439Sep 9, 2026
Sep 5, 2026Evran SedatEVP, Global Supply Chainoption exercise1,027$0.00—3,345Sep 9, 2026
Sep 5, 2026Evran SedatEVP, Global Supply Chaintax withholding329$386.11$127K3,016Sep 9, 2026
Sep 5, 2026Engelhardt Eva AnetteEVP, President, CDGoption exercise1,027$0.00—1,530Sep 9, 2026

Full insider history for Bio-Rad Laboratories, Inc.Class A, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BIO-RAD LABORATORIES, INC., CIK 12208 on EDGAR
Extract generated
November 8, 2026
Withheld
1 line-years whose four quarters do not sum to the filed year: operating income FY2016
Repaired
4 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2017, income tax FY2018, pretax income FY2018, operating income FY2025
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/BIO.json